$68.08 -0.21 (%) Alnylam Pharmaceuticals Inc - NASDAQ

Jul. 29, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  2. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  3. Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'

    Benzinga | Jan. 11, 2016 | 13:57PM EST
  4. Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B

    Benzinga | Dec. 7, 2015 | 10:30AM EST
  5. Breakaway Gaps By Stocks Can Be Scary But Profitable

    IBD | Dec. 3, 2015 | 17:58PM EST
  6. Leerink Highlights Biotechs Poised To Benefit From ASH Conference

    Benzinga | Nov. 30, 2015 | 13:13PM EST
  7. Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam ...

    GuruFocus | Nov. 17, 2015 | 10:50AM EST
  8. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga | Nov. 5, 2015 | 10:25AM EST
  9. Chardan Sees Promise Of ALN-PCSsc, Initiates The Medicines Co. With Buy

    Benzinga | Nov. 4, 2015 | 07:50AM EST
  10. Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

    Benzinga | Nov. 3, 2015 | 05:01AM EST
  11. Benzinga's Top Initiations

    Benzinga | Oct. 23, 2015 | 08:20AM EST
  12. Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

    Benzinga | Oct. 8, 2015 | 16:01PM EST
  13. Julian Robertson Boosts His Stakes in JD.com, Netflix

    GuruFocus | Oct. 6, 2015 | 14:44PM EST
  14. Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

    Benzinga | Oct. 6, 2015 | 14:08PM EST
  15. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD | Sep. 24, 2015 | 10:51AM EST
  16. Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias

    Benzinga | Sep. 15, 2015 | 07:00AM EST
  17. Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years

    Benzinga | Sep. 14, 2015 | 04:53AM EST
  18. 4 Biotechs Piper Jaffray Is Buying On The Pullback

    Benzinga | Aug. 26, 2015 | 15:27PM EST
  19. Here's One Biotech Stock JMP Analysts Are Very Bullish On

    Benzinga | Aug. 26, 2015 | 09:31AM EST
  20. Benzinga's Top Initiations

    Benzinga | Aug. 11, 2015 | 09:45AM EST
  21. Benzinga's Top Downgrades

    Benzinga | Aug. 7, 2015 | 09:34AM EST
  22. 5 Biotech Stocks On Deck With The FDA

    Benzinga | Jun. 30, 2015 | 13:39PM EST
  23. Julian Robertson Adds 16 New Stakes to Portfolio

    GuruFocus | Jun. 23, 2015 | 18:39PM EST
  24. Gurus Purchase Tekmira Pharmaceuticals in Q1

    GuruFocus | Jun. 19, 2015 | 17:57PM EST
  25. JMP Sees A 'Negative Market Tone' In Biotechnology

    Benzinga | Jun. 15, 2015 | 13:31PM EST
  26. Alnylam Reports Data on Potential Alexion Rival Drug

    IBD | Jun. 12, 2015 | 12:38PM EST
  27. US Stock Futures Slide Ahead Of Economic Data

    Benzinga | Jun. 12, 2015 | 07:22AM EST
  28. Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

    Benzinga | Jun. 12, 2015 | 06:05AM EST
  29. After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma

    Benzinga | May. 16, 2015 | 09:50AM EST
  30. Alnylam Pharmaceuticals

    IBD | Apr. 21, 2015 | 18:48PM EST
  31. Alnylam Says Neurological Drug Passes Midstage Study

    IBD | Apr. 21, 2015 | 13:22PM EST
  32. Morning Market Gainers

    Benzinga | Apr. 21, 2015 | 09:45AM EST
  33. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 21, 2015 | 08:13AM EST
  34. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga | Apr. 20, 2015 | 13:44PM EST
  35. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 16:31PM EST
  36. Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3

    Benzinga | Apr. 13, 2015 | 11:01AM EST
  37. Benzinga's Top Initiations

    Benzinga | Feb. 27, 2015 | 09:29AM EST
  38. Microsoft, Bank Of New York And Others Insiders Have Been Buying

    Benzinga | Feb. 2, 2015 | 08:57AM EST
  39. Deutsche Bank's Top Biotech Picks For 2015

    Benzinga | Jan. 22, 2015 | 11:09AM EST
  40. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher

    Benzinga | Jan. 21, 2015 | 15:10PM EST
  41. 4 More Biotech Secondaries Traders Are Watching

    Benzinga | Jan. 21, 2015 | 13:38PM EST
  42. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump On Upbeat Earnings

    Benzinga | Jan. 21, 2015 | 12:53PM EST
  43. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations

    Benzinga | Jan. 21, 2015 | 10:42AM EST
  44. Shares Of Alnylam Pharmaceuticals Lower Following Equity Offering

    Benzinga | Jan. 21, 2015 | 10:03AM EST
  45. Morning Market Losers

    Benzinga | Jan. 21, 2015 | 09:55AM EST
  46. Wednesday Morning Movers: Netflix Flying High

    Benzinga | Jan. 21, 2015 | 08:55AM EST
  47. Alnylam Pharmaceuticals

    IBD | Jan. 20, 2015 | 18:44PM EST
  48. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  49. Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias

    Benzinga | Jan. 5, 2015 | 08:02AM EST
  50. Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump

    Benzinga | Dec. 8, 2014 | 12:56PM EST
Trading Center